Uterine fibroids, also known as leiomyomas, are non-cancerous growths that develop in the uterus. They are common, particularly in women of reproductive age, and can lead to symptoms such as heavy menstrual bleeding, pelvic pain and reproductive issues. While traditional treatments for fibroids include surgical options like hysterectomy and myomectomy, there is a growing interest in conservative, less invasive approaches. One such method is radiofrequency (RF) myolysis, a technique that utilises energy to reduce the size and symptoms of fibroids.
What is RF Myolysis?
Radiofrequency myolysis is a minimally invasive procedure that uses thermal energy to ablate, or destroy, fibroid tissue. The process involves inserting a needle-like probe into the fibroid under ultrasound guidance. Once in place, the probe emits RF energy, generating heat that causes the fibroid cells to die and shrink over time. This technique can be performed via laparoscopy, transvaginally, or through the cervix, depending on the location and size of the fibroids.
Benefits of RF Myolysis
The Procedure
Before the procedure, patients undergo imaging studies, such as ultrasound or MRI, to map the size and location of the fibroids. During the procedure:
Outcomes and Efficacy
Research indicates that RF myolysis is effective in reducing fibroid size and alleviating symptoms. Studies report high patient satisfaction rates, with many experiencing significant improvement in menstrual bleeding and pelvic discomfort. Additionally, the procedure has shown promising results in preserving fertility, with some women successfully conceiving post-treatment.
Considerations and Risks
While RF myolysis is generally safe, it is not without risks. Potential complications include infection, bleeding and injury to surrounding tissues. It is also important to note that not all fibroids are suitable for RF myolysis. The size, number and location of fibroids, as well as the patient's overall health and reproductive plans, must be carefully considered.
Mediclinic City Hospital pioneers UAE’s first transcervical radiofrequency myolysis of fibroids